In our case, administration of the complement C5 inhibitor eculizumab led to marked clinical improvement after failure of high-dose steroid therapy.<h4>Conclusion</h4>This study suggests a consistent temporal pattern wherein MG predominantly precedes NMOSD, often by years, suggesting a possible shared autoimmune predisposition. The gene discussed is C5; the disease is myasthenia gravis.